論文(主なもののみ)

ここでは主なものだけ抜粋。

(*, corresponding author)      

     2024年

1. Miyakawa Y, *Otsuka M, Shibata C, Seimiya T, Yamamoto K, Ishibashi R, Kishikawa T, Tanaka E, Isagawa T, Takeda N, Kamio N, Imai K, Fujishiro M. Gut Bacteria-derived Membrane Vesicles Induce Colonic Dysplasia by Inducing DNA Damage in Colon Epithelial Cells. Cell Mol Gastroenterol Hepatol. 2024 Feb 1:S2352-345X(24)00010-9

2. Iwata T, *Kishikawa T, Seimiya T, Notoya G, Suzuki T, Shibata C, Miyakawa Y, Odawara N, Funato K, Tanaka E, Yamagami M, Sekiba K, Otsuka M, Koike K, Fujishiro M. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. J Biol Chem. 2024 Feb 10:105742.

　 2023年

1. Seimiya T, *Otsuka M, Fujishiro M.  Overcoming T-cell exhaustion: new therapeutic targets in HCC immunotherapy.  Hepatology. 2023;26(2):106021.

2. Seimiya T, Suzuki T, Iwata T, Kishikawa T, Sekiba K, Shibata C, Ishigaki K, Fujiwara H, Oyama H, Kanai S, Sato T, Nakai Y, Ishibashi R, Moriyama M, Nakagawa R, Ijichi H, *Otsuka M, Koike K. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. iScience. 2023;26(2):106021.

3. Shibata C, *Otsuka M, Shimizu T, Seimiya T, Kishikawa T, Aoki T, Fujishiro M. Extracellular vesicle‑mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro. Oncol Rep. 2023;50(5):194. 

4. Funato K, Miyake N, Sekiba K, Miyakawa Y, Seimiya T, Shibata C, Kishikawa T, *Otsuka M. Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA. Hepatol Commun. 2023;8;7(11):e0313.

2022年

1. Shibata C, *Otsuka M, Seimiya T, Kishikawa T, Ishigaki K, Fujishiro M.  Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. Clin Transl Med. 2022; 12: e1089.

2. *Otsuka M.  Letter to the editor to "Circulating Tumor DNA Guding Adjuvant Therapy in Colon Cancer". N Engl J Med. 2022; 387: 759-760.

     2021年 

1. Kishikawa T, Higuchi H, Wang L, Panch N, Maymi V, Best S, Lee S, Notoya G, Toker A, Matesic L, Wulf G, Wei W, Otsuka M, Koike K, Clohessy J, Lee YR, *Pandolfi PP. WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. J Clin Invest. 2021; 131(24): e140436.

2. Sekiba K, *Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, Yamagami M, Tsutsumi T, Okushin K, Miyakawa K, Ryo A, Koike K. Hepatitis B Virus X Protein-Induced Degradation of Smc5/6 Complex Impairs Homologous Recombination-Mediated Repair of Damaged DNA. J Hepatol. 2022;76(1): 53-62.

3. Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Seimiya T, Sekiba K, Ohno M, Iwata T, Ishibashi R, *Otsuka M, Koike K. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther. 2022; 29: 505-518.

    2020年 

1. Seimiya T, *Otsuka M, Iwata T, Tanaka E, Sekiba K, Shibata C, Moriyama M, Nakagawa R, Maruyama R, Koike K. Aberrant expression of a novel circular RNA in pancreatic cancer. J Human Genet. 2021;66(2):181-191. 

2. *Otsuka M, Koike K. Should level of HBV-RNA be used to determine when patients should stop treatment with nucleos(t)ide analogues (Editorial) Clin Gastroenterol Hepatol. 2020;18(3):551-552.

    2019年

1. Sekiba K, *Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, Suzuki T,  Tanaka E, Ishibashi R,  Funato K, Koike K. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology. 2019;69(5):1903-1915. 

2. Sekiba K, *Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Inhibition of HBV  transcription from cccDNA with nitazoxianide by targeting HBx-DDB1 interaction. Cell Mol Gastroenterol Hepatol.  2019;7(2):297-312.

    2017年

1. Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, Koike K. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc Natl Acad Sci U S A. 2017 ;114(19):E3806-E3815..

2. Yoshikawa T, Wu JF, *Otsuka M, Kishikawa T, Suzuki N, Takata A, Ohno M, Ishibashi R, Yamagami M, Nakagaw R, Kato N, Miyazawa M, Han J, Koike K. Repression of miRNA Function Mediates Inflammation-associated Colon Tumorigenesis. Gastroenterology 2017 Feb;152(3):631-643.

    2016年

1. Kishikawa T, *Otsuka M, Yoshikawa T, Ohno M, Ijichi H, Koike K. Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1. Nat Commun. 2016;7:13006.

2. Kishikawa T, *Otsuka M, Yoshikawa T, Ohno M, Yamamoto K, Yamamoto N,Kotani A, Koike K. Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight. 2016;1(8):e86646.

    2015年

1. Kang YJ, Bang BR, Han KH, Hong L, Shim EJ, Ma J, Lerner R, Otsuka M. Regulation of NKT cell-mediated immune responses to tumors and liver inflammation by mitochondrial PGAM5−Drp1 signaling. Nat Commun. 2015;6:8371.

2. Yoshikawa T, Wu JF, *Otsuka M, Kishikawa T, Ohno M, Shibata C, Takata A, Han F, Kang YJ, Chen CY, Shyu AB, Han J, Koike K. ROCK inhibition enhances microRNA function by promoting deadenylation of targeted mRNAs via increasing PAIP2 expression. Nucleic Acids Res. 2015;43(15):7577-89.

    2013年

1. Ma J, Bang BR, Lu J, Eun SY, Otsuka M, Croft M, Tobias P, Han J, Takeuchi O, Akira S, Karin M, Yagita H, Kang YJ. The tumor necrosis family member 4-1BBL sustains inflammation by interacting with TLR signaling components during late-phase activation. Sci Signal. 2013;6:ra87.

2. Takata A, *Otsuka M, Yoshikawa T, Kishikawa T, Hikiba Y, Obi S, Goto T, Kang Y, Maeda S, Yoshida H, Omata M, Asahara H, Koike K. MiRNA-140 acts as a liver tumor suppressor by controlling NF-kB activity via directly targeting Dnmt1 expression. Hepatology 2013 57(1):162-70.

    2011年 

1. Kojima K, Takata A, Vadnais C, *Otsuka M , Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K.  MicroRNA122 is a key regulator of α-fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma. Nat Commun. 2011;2: 338.

2. Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, Koike K, Kamatani N, Kubo M, Nakamura Y, Matsuda K. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011;43(5):455-8.

　2010年

1. Kang YJ#, Otsuka M#, van den Berg A, Hong L, Huang Z, Wu X, Zhang DW, Vallance BA, Tobias PS, Han J. Epithelial p38a Controls Immune Cell Recruitment in the Colonic Mucosa. PLoS Pathog.2010 Jun 3;6(6):e1000934. (#; equally contributed)

2. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, Han J. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology. 2010;138(4):1255-65.

　2008年

1. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S, Han J. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest. 2008;118(5):1944-1954.

2. Dharel N, Kato N, Muroyama R, Taniguchi H, Otsuka M, Wang Y, Jazag A, Shao RX, Chang JH, Adler MK, Kawabe T, Omata M. Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus. Hepatology. 2008;47(4):1136-49.

   2007年

1. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook  R, Das SC, Pattnaik AK, Beutler B, Han J. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity. 2007;27:123-34.

2. Kang YJ, Kim SO, Shimada S, Otsuka M, Seit-Nebi A, Kwon BS, Watts TH, Han J. Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat. Immunol. 2007;8:601-9.